/

2162.HK

KEYMED BIO-BClosed

77.15−1.20 −1.53%HKD

HKSE · as of Oct 14, 04:08 ET · 15m delay

Open

77.20

Prev close

78.35

Day range

75.4079.20

52-week range

44.6689.75

Volume

2.39M1.13×

Mkt cap

22.73B

P/E ttm

26.15

Fwd P/E

187.85

EPS ttm

2.95

Div yield

0.00%

Earnings

—

From 52w high

−14.04%

Price Chart

Yahoo Finance · delayed

2162.HKOct 14, 2026O 77.20H 79.20L 75.40C 77.15−1.20 (−1.53%)Vol 2.39M

SMA 5077.74
SMA 20067.48

1Y change +13.62% since Oct 13, 2025 close529 bars loadedTimes in Asia/Hong_KongDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

2162.HK KEYMED BIO-B · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −0.45%
1 month: +2.94%
3 months: −11.42%
6 months: −2.71%
Year to date: +45.29%
1 year: +19.61%

Valuation & ownership

Market cap: 22.73B
Enterprise value: 20.55B
P/E (ttm): 26.15
Forward P/E: 187.85
PEG ratio: —
Price / book: 4.84
Price / sales (ttm): 27.23
EV / EBITDA: -34.09
EPS (ttm): 2.95
EPS (forward): 0.4107
Beta (5y monthly): -0.16
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 294.60M
Float: 219.45M
Short % of float: —
Short ratio (days): —
Held by insiders: 25.16%
Held by institutions: 32.64%
Avg volume (3m): 2.11M
50-day average: 77.72
200-day average: 67.61
52-week change: +19.61%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 49.5
vs 50-day SMA: −0.76%
vs 200-day SMA: +14.34%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 5.25%
Realised vol (20d, ann.): 62.4%
From 52-week high: −14.04%
From 52-week low: +72.75%

ANR

Analyst Consensus

11 analysts

Consensus

—

Mean target

104.01

+34.81% implied

Low 90.51Median 104.45High 119.34

Recommendation trend

Now15 / 0 / 0
1m ago15 / 0 / 0

DES

About KEYMED BIO-B

Yahoo Finance profile

Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis; CMG901/AZD0901, an antibody drug conjugate for treatment of advanced solid tumors; CM512, a TSLP x IL-13 bispecific antibody in Phase I clinical study; and CM518D1, an antibody drug conjugate drug in open-label Phase I/II clinical trial. It is also developing CM336, a CMA x CD3 bispecific antibody in an open-label Phase I/II clinical study for the treatment of patients with relapsed or refractory multiple myeloma; CM313 in Phase II clinical study in subjects with primary immune thrombocytopenia; CM383, an Aß protofibrils antibody in Phase Ib clinical study; and CM559, a N3pG Aß antibody in Phase I clinical study. In addition, the company is involved in the development of CM350, a GPC3 x CD3 bispecific antibody in Phase I/II clinical study; CM326, a TSLP antibody; CM355/ICP-B02/PRO-203, a CD20 x CD3 bispecific antibody; and CM369/ICP-B05, an anti-C-C motif chemokine receptor 8 monoclonal antibody. It has an out-licence agreement with Belenos Biosciences, Inc.; Platina Medicines Ltd; Prolium Biosciences, Inc.; and Timberlyne Therapeutics, Inc. The company was formerly known as 2Health Biosciences, Inc. Keymed Biosciences Inc. was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.

Sector: Healthcare
Industry: Biotechnology
Employees: 1,768
Headquarters: Chengdu, China
Website: keymedbio.com
Officers

SEAS

Seasonality · 2162.HK

2021–2026 · monthly returns

Strongest month Jul +13.22%Weakest month Dec −14.58%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	4.8	-6.8	17.1	24.5	-18.2	14.5	3.3	2.7	8.7	-5.4			+45.3%
2025	-4.2	18.3	26.0	0.6	-1.2	4.8	32.9	12.6	7.4	-18.9	3.5	-14.8	+70.7%
2024	-37.1	10.8	-1.0	0.1	-5.2	4.8	-6.8	12.1	18.3	-0.4	-7.7	-18.9	−36.7%
2023	31.8	-6.2	-7.9	7.8	-34.8	0.4	34.4	-2.9	-6.5	16.6	-3.5	-12.6	−3.7%
2022	-23.0	8.5	-24.4	6.7	2.2	39.8	-7.6	15.2	1.3	26.4	12.3	0.9	+48.7%
2021								-18.0	1.0	-22.3	18.2	-27.5	−44.8%

2162.HK

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

2162.HK

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About KEYMED BIO-B

Seasonality · 2162.HK

Insider Activity · 2162.HK

Congress Trades · 2162.HK

Investors Holding 2162.HK

Investors Holding 2162.HK

Congress Trades · 2162.HK

Insider Activity · 2162.HK

Seasonality · 2162.HK

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About KEYMED BIO-B

Financial Snapshot

Earnings & Dividends

News